- Home
- TSHA vs KALV Comparison
TSHA vs KALV Comparison
Compare TSHA & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- KALV
- Stock Information
- Founded
- TSHA 2019
- KALV N/A
- Country
- TSHA United States
- KALV United States
- Employees
- TSHA N/A
- KALV N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- TSHA Health Care
- KALV Health Care
- Exchange
- TSHA Nasdaq
- KALV Nasdaq
- Market Cap
- TSHA 469.3M
- KALV 523.1M
- IPO Year
- TSHA 2020
- KALV N/A
- Fundamental
- Price
- TSHA $2.04
- KALV $12.34
- Analyst Decision
- TSHA Strong Buy
- KALV Strong Buy
- Analyst Count
- TSHA 9
- KALV 2
- Target Price
- TSHA $6.22
- KALV $26.00
- AVG Volume (30 Days)
- TSHA 1.1M
- KALV 249.2K
- Earning Date
- TSHA 08-12-2024
- KALV 09-05-2024
- Dividend Yield
- TSHA N/A
- KALV N/A
- EPS Growth
- TSHA N/A
- KALV N/A
- EPS
- TSHA N/A
- KALV N/A
- Revenue
- TSHA $12,873,000.00
- KALV N/A
- Revenue This Year
- TSHA N/A
- KALV N/A
- Revenue Next Year
- TSHA N/A
- KALV $593.39
- P/E Ratio
- TSHA N/A
- KALV N/A
- Revenue Growth
- TSHA 34.05
- KALV N/A
- 52 Week Low
- TSHA $1.27
- KALV $7.21
- 52 Week High
- TSHA $4.32
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- TSHA 41.04
- KALV 44.36
- Support Level
- TSHA $2.02
- KALV $12.14
- Resistance Level
- TSHA $2.15
- KALV $13.52
- Average True Range (ATR)
- TSHA 0.12
- KALV 0.67
- MACD
- TSHA -0.01
- KALV 0.01
- Stochastic Oscillator
- TSHA 13.70
- KALV 43.21
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.